What's new?

Paris, France, July 10th. 2018. Sofinnova Partners, a leading venture capital firm specialized in Life Sciences, today announced that Otsuka Holdings is acquiring its portfolio company ReCor Medical, a medical device company specialized in the treatment of hypertension. The terms of the acquisition are being withheld due to non-disclosure obligations.

ReCor Medical was created in 2009 by Sofinnova Partners, Mano Iyer – who was then entrepreneur-in-residence at Sofinnova Partners and now Chief Operating Officer of ReCor – and Professor Jacques Seguin, MD, who became a large private investor in ReCor. Prof. Seguin was previously founder and CEO of CoreValve, a past Sofinnova portfolio company and a leader in the transcatheter valve replacement space, which was sold to Medtronic. Sofinnova Partners was the sole venture capital investor in ReCor Medical and remained its largest shareholder until the sale to Otsuka.

ReCor Medical is an innovative medical device company that developed the Paradise System, a proprietary ultrasound ablation system for renal denervation (RDN). RDN is a new potential therapeutic approach for the treatment of hypertension, one of the most prevalent medical conditions. ReCor recently announced positive results of its landmark RADIANCE-HTN SOLO hypertension study at EuroPCR 2018.

Antoine Papiernik, Managing Partner at Sofinnova Partners and ReCor Board Member, said: “ReCor perfectly illustrates our investment strategy: we worked hand-in-hand with Mano Iyer to create the business vision and plan for ReCor. We then founded and funded the company, and opened our network of experts, key opinion leaders and board members to help grow it. We brought trusted entrepreneurs Jay Watkins as Chairman and Andy Weiss as CEO to help guide and operate the company through to a corporate transaction to our partner Otsuka.”

Jay Watkins, Chairman of ReCor Medical said: “Sofinnova Partners remains one of few VCs willing to fund early-stage med-tech ventures targeting large and important new markets. The firm played a critical role throughout ReCor’s life, and has proven to be a reliable, value-added partner for the company. The field of renal denervation has been a complex one over the last few years with periods of euphoria and periods of doubt. Sofinnova Partners’ support remained constant throughout, helping to build a strong partnership with Otsuka and then navigate through the challenges to a very successful trade sale.”

Mano Iyer, Founder and COO of ReCor Medical added: “ReCor is a success story because Sofinnova Partners, consistent with its philosophy, saw the value of an opportunity which did not yet exist. It had the vision to create and fund the company, not only in the very beginning, but also during the critical early years. Despite the dramatic swings in the field, Sofinnova Partners’ confidence in me and in the management team was essential to keep us motivated when others lost hope. This great exit is therefore particularly sweet.”

Andrew M. Weiss, CEO of ReCor Medical adds: “I came to ReCor thanks to Antoine Papiernik’s introduction to the company. With his help, our team developed the partnership with Otsuka and was able to remain focused on value creation. The recent announcement of our positive RADIANCE-HTN SOLO study results and now the merger with Otsuka demonstrate that our teamwork with Sofinnova Partners was successful. We now have an opportunity to transform the treatment of hypertension and benefit millions of potential patients while providing a solid return for our investors. I look forward to continuing to work to make this technology a possible standard of care in hypertension treatment”.

For more information, please contact:
International: Anne Rein
Tel: +33 6 03 35 92 05
e-mail: anne.rein@strategiesimage.com
United States: Kate Barrette
Tel: +1 212 223 0561
e-mail: kbarrette@rooneyco.com

About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, the firm brings together a team of professionals from all over Europe, the US and China. The firm focuses on paradigm shifting technologies alongside visionary entrepreneurs. Sofinnova Partners seeks to invest as a lead or cornerstone investor in seed, start-ups, corporate spin-offs and late stage companies. It has backed nearly 500 companies over more than 45 years, creating market leaders around the globe. Today, Sofinnova Partners has over €1.9 billion under management. For more information: www.sofinnova.fr

About ReCor Medical, Inc.
ReCor Medical is a medical device company that designs and manufactures the Paradise System, a proprietary ultrasound ablation system for renal denervation (RDN). RDN is a new potential therapeutic approach for the treatment of hypertension, one of the most prevalent medical conditions. The Paradise System is approved for sale in the EU and bears a CE mark, but is not approved for sale in the United States. The System’s intravascular catheters denervate renal nerves by combining the protection of water-based cooling of the renal artery with high intensity ultrasound energy for circumferential renal nerve ablation. The Paradise System has been studied in clinical trials of approximately 300 patients to date. Following the positive outcomes of the RADIANCE-HTN SOLO trial, ReCor will continue its evaluations of Paradise in RADIANCE-HTN TRIO (a feasibility study of patients with resistant hypertension) and REQUIRE (a pivotal study of patients with resistant hypertension in Japan and Korea), and launch the RADIANCE II pivotal study (a study of patients with moderate hypertension) in the United States and Europe.

About Otsuka Holdings Co., Ltd. and Otsuka Medical Devices Co., Ltd.
Otsuka Holdings Co., Ltd. is the holding company of the Otsuka group, a global healthcare group headquartered in Tokyo, Japan. With operations in pharmaceuticals, nutraceuticals, medical devices and other health-related businesses, the group generated worldwide sales of JPY1,240 billion in the fiscal year ended December 2017.

Established in 2011, Otsuka Medical Devices Co., Ltd. is a fully-owned subsidiary of Otsuka Holdings and one of its core operating subsidiaries. Otsuka Medical Devices focuses on the development and commercialization of endovascular devices that provide new therapeutic options in areas where patient needs cannot be met through pharmaceutical or other conventional treatment.
Otsuka Medical Devices conducts the REQUIRE trial for renal denervation in hypertensive patients (n=140), who are uncontrolled on 3 or more medications including a diuretic, in Japan and Korea through its subsidiary JIMRO Co., Ltd.


Palo Alto, California and Copenhagen, Denmark, September 13th, 2011 – Ascendis Pharma, a privately held specialty pharmaceutical company, today announced positive results of a Phase 2 clinical study of ACP-001 in growth hormone deficient adults. The Phase 2 clinical study met all primary and secondary endpoints, the primary efficacy endpoint being the change in IGF-I levels from baseline compared to daily growth hormone. Conducted in a number of Western European countries, the Phase 2 trial was designed to investigate safety, tolerability, pharmacokinetics and pharmacodynamics in 37 adult patients with growth hormone deficiency. The study was a randomized, four-week, multiple-dose study comparing three dose levels of once-weekly ACP-001 to daily growth hormone.

ACP-001 administered once-weekly was as effective in stimulating IGF-I as seven daily injections of the equivalent weekly dose of growth hormone. ACP-001 stimulated a doseproportional increase in IGF-I levels across the three dose levels. IGF-I exposure was maintained throughout the week, thereby achieving a low peak-to-trough ratio. The Phase 2 trial also confirmed the positive safety profile of ACP-001 previously observed in the Phase 1 clinical trial, and safety comparable with daily growth hormone. No treatment-emergent anti-hGH antibody formation was observed during this multiple-dose trial.

ACP-001 was administered as a subcutaneous injection through a very fine needle (30G), and no difference in injection-site reactions were noted between ACP-001 and daily growth hormone.

“I am excited that Ascendis has advanced this once-weekly growth hormone to the pointthat its efficacy and safety has been established in adult patients with growth hormone deficiency. The once-weekly profile of our product meets the goals of patients and endocrinologists worldwide. We look forward to continuing clinical trials in both adults as well as children with growth deficiency.” stated Jan Møller Mikkelsen, President and Chief Executive Officer of Ascendis Pharma.

About ACP-001
Ascendis Pharma is developing ACP-001 for the treatment of children and adults with growth hormone deficiency. Today, these patients are treated with daily injections of growth hormone. ACP-001 is a human growth-hormone prodrug that releases efficacious levels of unmodified human growth hormone in a controlled manner, allowing the drug to be administered once weekly. ACP-001 is unique in that it is an inactive prodrug that releases free growth hormone identical to endogenous growth hormone, maintaining the same physiological actions as growth hormone released from the pituitary. For further information on the characteristics and advantages of ACP-001, please go to http://www.ascendispharma.com/pipeline/growth-hormone
The annual market for human growth hormone is currently $3 billion, with sales continuing to grow.

About Ascendis Pharma
Ascendis Pharma is focused on fast and low-risk internal development of differentiated versions of marketed high-value specialty drugs. Ascendis is the leading company in transient conjugation technology, enabling clinically superior long-acting versions of proteins, peptides and small molecules.
Ascendis Pharma creates clinically differentiated drugs using the company’s innovative prodrug technology platform, TransCon. The reversible TransCon linkers conjugate peptides, proteins and small molecules to carrier molecules in a transient manner. This unique reversibility allows the release of unmodified active drug from the prodrug in a controlled, sustained-release fashion.
In addition to ACP-001, Ascendis Pharma has five other products in its internal portfolio. In the field of diabetes, Ascendis has a large strategic collaboration with Sanofi which includes product opportunities created via TransCon technology such as a once-weekly insulin product, a once-monthly GLP-1 product, and a fixed-dose combination of insulin and GLP-1 for weekly administration.

Jan Møller Mikkelsen, President and CEO, Ascendis Pharma (+1) 650 617 3407.


Visit website http://www.ascendispharma.com


SpineVision société spécialisée dans la conception et la commercialisation d’implants rachidiens vient de clôturer un second tour de table d’un montant de 6M d’euros apportés par Sofinnova Partners et par le fonds suisse New Medical Technologies (NMT) à hauteur, respectivement, de 2 et 4 M d’euros. Sofinnova Partners, représentée au conseil d’administration de SpineVision par Antoine Papiernik, partenaire-associé, avait déjà apporté 2 M d’euros à l’entreprise lors de sa création.

Les caractéristiques innovantes et propriétaires des produits et l’étendue de la gamme proposée, son positionnement dans un marché à fort potentiel, l’équipe expérimentée à l’origine de SpineVision : tous ces éléments nous ont beaucoup séduit et nous ont amené à financer l’entreprise dès sa création en 1999. Un an et demi plus tard, nous sommes convaincus que cette entreprise a les atouts déterminants pour devenir un acteur important de son domaine, déclare Antoine Papiernik.

André Lamotte, de New Medical Technologies ajoute : SpineVision est très bien positionné sur un marché potentiel de 2 Mds de $, les premiers produits présentés, tous en phase clinique, séduisent les chirurgiens concernés et nous sommes ravis de rentrer au capital de la société à ce stade de son développement.

Le premier tour de table avait pour but de financer le développement de la gamme d’implants jusqu’à leur homologation et leur mise sur le marché ; ce nouvel apport de 6 M d’euros doit financer la phase de commercialisation et notamment la mise en place des structures opérationnelles de SpineVision aux Etats-Unis, territoire qui représente à ce jour 50% du marché mondial et pour lequel les premières interventions cliniques sont prévues dès le 4ème trimestre de cette année. En outre, SpineVision prévoit de lancer la commercialisation de ses produits sur le continent asiatique dans le courant de l’année 2002.

SpineVision, fondée par des spécialistes de l’instrumentation médicale, s’adresse à l’ensemble des Orthopédistes et des Neurochirurgiens du rachis et a pour ambition de proposer une nouvelle gamme complète de produits. Ils sont destinés à l’ensemble des pathologies de la colonne vertébrale, depuis la scoliose jusqu’aux indications propres aux vertèbres cervicales, en passant par les problèmes de dégénérescence des disques intervertébraux.

Gérard Vanacker, PDG de SpineVision : SpineVision, nous en sommes convaincus, représente une bonne opportunité d’investissement ; l’équipe que nous avons constitué a prouvé qu’elle pouvait tenir ses engagements, et compte bien s’imposer à présent comme nouveau spécialiste de ce marché en manque de réelles nouveautés. Pour preuve, le fait que notre investisseur d’origine nous renouvelle sa confiance et l’arrivée d’un second investisseur prestigieux dans notre capital et ce, pour des montants importants. Nous avons dorénavant les moyens de lancer notre gamme sur l’ensemble de nos marchés dans d’excellentes conditions, afin que le plus grand nombre de chirurgiens, et leurs patients, puissent apprécier les avancées technologiques de nos produits.

A propos de Sofinnova Partners :Sofinnova Partners, basée à Paris depuis 1972, est une société de capital-risque spécialisée dans le financement de projets à fort potentiel à un stade précoce de leur développement. Elle soutient depuis son origine des entreprises appartenant à deux secteurs d’activité spécifiques : les sciences de la vie et les technologies de l’information. Elle est managée par 8 partenaires-associés et gère plus de 500 M d’euros de fonds. Dans le domaine des sciences de la vie, elle privilégie les investissements liés à la biopharmacie et à l’instrumentation médicale et a notamment été investisseur-fondateur dans des entreprises comme Genset, Cerep, NicOx, Actelion et NovusPharma. Depuis 1996, Sofinnova Partners a réalisé 50 investissements dont 31 en tant que chef de file.

A propos de New Medical Technology : New Medical Technology est la première société de capital risque suisse dans le domaine de la santé. Elle est spécialisée dans la création d’entreprises et autres investissements ciblés. Son principal objectif est de lancer et d’accompagner des sociétés compétitives situées dans le couloir rhodanien. Elle recherche des opportunités d’investissements par la découverte de technologies biopharmaceutiques et médicales dans les Universités, les structures privées, comme dans des spin-off de grands groupes. NMT a un capital de 296 M CHF.

Contacts :

Antoine Papiernik Sofinnova Partners Tel: 33 1 53 05 41 00

Marie-Carole de Groc Euro RSCG Omnium Tel : 33 1 41 34 49 90

Visit website http://www.spinevision.com


SpineVision, a company specializing in the design and marketing of spinal implants, has just finalised a second round of financing totaling six million Euros contributed by Sofinnova Partners and by the Swiss fund New Medical Technologies (NMT), in the respective amounts of two and four million Euros. Sofinnova Partners, represented on the board of directors of SpineVision by Antoine Papiernik, General Partner, had already contributed two million Euros to the company at the time of its creation.

With its innovative, broad and proprietary product range, its positioning in a high-potential market, and an experienced team at the origin of the firm, Spinevision was immediately very appealing to us and led us to finance the company as of its creation in 1999. A year and a half later, we are convinced that Spinevision has what it takes to become a major player in its field, Antoine Papiernik said.

André Lamotte, of New Medical Technologies, added: SpineVision is very well positioned in a potential market of $2 billion. The first products developped by the company, all currently in clinical evaluation, are appealing to the surgeons concerned, and we are extremely pleased to enter the capital of this company at this stage of its development.

The purpose of the first round was to fund the development of the range of implants until their certification and market introduction; the new contribution of six million Euros is meant to finance the marketing phase, including, in particular, the establishment of SpineVision’s structures in the United States, a territory which represents to date 50% of the world market and for which the initial clinical operations are scheduled for the 4th quarter of this year already. Furthermore, SpineVision plans to begin marketing its products on the Asian continent during the year 2002.

SpineVision, founded by specialists of medical instruments, targets all of the Orthopedists and Neurosurgeons of the spine. Its ambition is to propose a new, complete range of products designed to deal with all vertebral column disorders, from scoliosis to indications specific to cervical vertebrae, including intervertebral disk degeneration problems.

Gérard Vanacker, CEO of SpineVision: We are convinced that SpineVision represents a good investment opportunity; the team that we have put together has demonstrated that it can reach its objectives and we now intend to position the company as the new specialist of a market in need of real innovations. The proof is the renewed confidence placed in us by our original investor and the entry in our capital of another prestigious investor, both for substantial amounts. We will now have the means to launch our range of products on all of our markets in excellent conditions, in such a manner that the largest number of surgeons — and their patients — may appreciate the technological advances embodied in them.

Concerning Sofinnova Partners: Sofinnova Partners, based in Paris since 1972, is a venture capital company specializing in the funding of high-potential projects at an early stage of development. Since its origin, it has supported businesses in two specific sectors of activity — life sciences and information technology. It is managed by eight partners and administers funds totaling more than 500 million Euros. In the field of life sciences, it gives priority to investments relating to bio-pharmaceuticals and medical devices. In particular, it was a financial founder of such firms as Genset, Cerep, NicOx, Actelion and NovusPharma. Since 1996, Sofinnova Partners has made 50 investments, including 31 as lead investor.

Concerning New Medical Technology : NMT New Medical Technologies is the first healthcare venture capital company in Switzerland, specializing in start-up companies and other selected investments. Its main objective is to start and build up globally competitive companies in the Alpine Rim. NMT seeks investment opportunities in breakthrough biopharmaceutical and medical technologies from universities and other private entities, as well as spin-offs from large corporations. NMT also makes carefully timed, value-driven investments in existing late stage private and promising small undervalued public companies on a worldwide basis, especially in the U.S.A. Since the capital increase of November 2000, NMT operates with a committed capital of CHF 296 million.

Contact persons:

– Antoine Papiernik Sofinnova Partners Tel: 33 1 53 05 41 00 

– Marie-Carole de Groc Euro RSCG Omnium Tel: 33 1 41 34 49 90

Visit website http://www.spinevision.com


Neurotech S.A., a specialist in the discovery, development and commercialization of cell-based therapies in the eye and the central nervous system (CNS), announces today that it has raised Euro 35 million in a pre-IPO funding round. The additional funds will allow Neurotech to progress several key projects towards clinical trials.

Joint lead investors in this round of funding were Apax Partners and Merlin Biosciences. Other new investors are Westdeutsche Landesbank Girozentrale, ABN Amro, Rothschild, and AGF Innovation. Existing investors (3i Plc, GIMV, Atlas Ventures, CDC Innovation, Sofinnova, Sudinnova, Banque de Vizille, Banexi, Private Equity Holdings and IMH) also participated.

“To achieve this level of funding in the current climate is a clear endorsement of Neurotech’s technology and business strategy,” said Dr Tom Shepherd, CEO of Neurotech. “It illustrates an increasing trend for European companies to raise more significant amounts of capital as they move into clinical trials instead of relying on drip-feed financing. We are delighted to have the support of such a range of quality investors in the biopharmaceutical field.”

The eye and central nervous system have large areas of unmet medical need. This is due not only to the complexity of the diseases, but also to the presence of the blood-eye and blood-brain barriers, which limit local access of orally or systemically applied molecules. Medicaments can be injected directly into the brain or eye, but this is an impractical approach if regular administration is required. It is primarily for this reason that protein therapeutics have never been developed in the eye. Cell therapy, either encapsulated or naked, allows the continuous local production and release of therapeutic molecules from living cells following a single administration. In addition the eye is an optimal site for cell therapy because it is easily accessible, can be visualised directly, and consists of a localised space with a small internal volume.

Neurotech’s core technology uses genetically modified eye and CNS derived cell lines, either encapsulated as a means of locally delivering proteins over long periods of time, or as a cell therapy to replace damaged cells. The company has a strong portfolio of cell-based therapies in development to treat CNS and eye diseases. Neurotech’s research success has been built up on solid collaborations and alliances with leading academic institutions such as the Institute of Ophthalmology in London, the Kennedy Krieger Institute in Baltimore, and the Foundation Fighting Blindness.

The company has recently successfully concluded pre-clinical trials in the field of Retinitis Pigmentosa and Age-related Macular Degeneration. The Euro 35 million will allow Neurotech to complete a number of agreements to bring new technologies into the company and to commence additional clinical trials in three main areas:

Retinitis Pigmentosa
Age-related Macular Degeneration, the main cause of blindness in adults
neovascular diseases of the eye
“Neurotech has a highly innovative and competitive approach to addressing neurological and ophthalmic disorders, which form a large market of unmet medical need,” said Mark Clement, Managing Director of Merlin Biosciences’ European Activities, who will be joining the Neurotech board. “The company has an excellent blend of research and development expertise based both in Evry, France, and Rhode Island, US, together with strong product offering. In particular the company’s proprietary encapsulated cell technology (ECT), constitutes one of the few competitive solutions to eye diseases and offers a delivery mechanism for broader CNS disorders. Furthermore, the management team under Tom Shepherd has the proven business and product development experience to make Neurotech a world leader in its field.”

“Neurotech, which I have been watching since its start up, has made highly significant progress, especially when it acquired the encapsulated cell technology (ECT), and when it broadened its focus to eye diseases, where there are clearly unsatisfied needs and huge market potential,” said Dr Laurent Ganem, General Partner of Apax Partners, who will become a board member of Neurotech. “With this substantial financing, we are very pleased to support Tom and his team in the further development of the company.”

Media/analyst contacts:

Andrew Lloyd & Associates Andrew Lloyd – +44-1273 675100 – allo@ala.com

Neurotech: Dr Tom Shepherd – +33-1 60 87 89 13 t.shepherd@neurotech.fr

(1) including Altamir & Cie, listed on Nouveau Marché. Founded and managed by Apax Partners & Cie, Altamir aims to co-invest and divest under the same conditions on a pari passu basis, in each company selected by Apax Partners & Cie private equity funds.

Visit website http://www.neurotech.fr


Neurotech S.A., société de biotechnologie spécialisée dans la découverte, le développement et la commercialisation de thérapie cellulaire et de systèmes de délivrance de protéines pour l’oeil et le cerveau, annonce aujourd’hui qu’elle a levé 35 millions d’Euros lors de son troisième tour de table, préalable à son introduction en bourse. Cette levée considérable permettra en particulier à Neurotech d’accélérer ses développements en phase clinique.

Apax Partners et Merlin Biosciences sont les deux chefs de file de ce tour de table qui réunit également de nouveaux investisseurs (Westdeutsche Landesbank Girozentrale, ABN Amro, Rotschild, et AGF Innovation) ainsi que les investisseurs déjà présents (3I Plc, GIMV, Atlas Venture, CDC Innovation, Sofinnova, Sudinnova, Banque de Vizille et IMH) qui y ont également participé.

« Réussir à réunir de tels fonds dans le climat actuel est une preuve de la confiance des investisseurs dans les technologies et la stratégie de Neurotech », déclare le Dr Tom Shepherd, Président Directeur Général de Neurotech. « Cela illustre parfaitement la tendance croissante des sociétés européennes qui privilégient désormais les fortes levées de capitaux lors de l’entrée en phase clinique. Nous nous réjouissons d’avoir le soutien d’investisseurs d’une telle qualité et reconnus dans le domaine bio-pharmaceutique. »

L’oeil et le système nerveux central restent des domaines à forts besoins médicaux non satisfaits. Ce n’est pas seulement dû à la complexité des maladies, mais également à la présence des barrières rétinienne dans l’oeil et hémato-encéphalique dans le cerveau, qui limite l’accès des molécules appliquées par voies orale ou systémique. Certains médicaments peuvent être directement injectés dans le cerveau ou l’oeil mais une telle approche est difficilement applicable en cas d’administration prolongée ou de pathologies chroniques. C’est la raison principale pour laquelle les protéines thérapeutiques n’ont jamais été développées dans l’oeil. La thérapie cellulaire, sous forme encapsulée ou non, permet une production locale, continue et à long terme de molécules thérapeutiques par les cellules vivantes après une seule administration chez le patient. De plus, l’oeil est le site de choix pour la thérapie cellulaire, car immuno-privilégié, facilement accessible, directement visualisable par simple examen ophtalmologique, et pourvu d’un volume intérieur faible.

La technologie principale de Neurotech utilise des lignées cellulaires génétiquement modifiées, dérivées de l’oeil et du cerveau. Ces cellules peuvent être encapsulées dans un implant oculaire pour permettre la délivrance locale des substances thérapeutiques sur de longues périodes, ou utilisées en thérapie substitutive pour remplacer les cellules endommagées, du patient. La société possède un portefeuille solide et diversifié de thérapies cellulaires en phase de développement pour soigner les maladies de l’oeil et du système nerveux central. Le succès de la recherche de Neurotech s’est construit par des accords et des partenariats avec des institutions académiques prestigieuses telles que « l’Institute of Ophtalmology in London », le « Kennedy Krieger Institute » à Baltimore, et la « Foundation Fighting Blidness » aux Etats-Unis.

La société a récemment mené à bien des essais pré-cliniques dans le domaine de la rétinite pigmentaire et la dégénérescence maculaire liée à l’âge (DMLA). Ces 35 millions d’Euros permettront à Neurotech de conclure de nombreux accords pour incorporer de nouvelles technologies dans la société, et ainsi débuter de nouveaux essais cliniques dans trois principaux domaines :

… la rétinite pigmentaire

… la DMLA, cause majeure de cécité chez les adultes

… les maladies néo-vasculaires de l’oeil

« Neurotech a une approche innovante et compétitive pour cibler les pathologies ophtalmiques et neurologiques représentant un immense marché sans traitement. » affirme Mark Clement, Directeur des activités européennes de Merlin Biosciences, qui va devenir Administrateur de Neurotech. « La société dispose à la fois d’un fort savoir-faire en Recherche et Développement, au Génopôle d’Evry et à Rhodes Island (USA), et d’une excellente offre de produits. La technologie propriétaire d’encapsulation de cellules (ECT) de Neurotech constitue une des rares solutions compétitives pour offrir une possibilité de traitement des pathologies de l’¦il et du système nerveux central. Nous faisons confiance en l’expérience, en termes de business et de développement de produits, de l’équipe de management, autour de Tom Shepherd pour faire de Neurotech un leader mondial dans son domaine. » « Neurotech, que je suis depuis ses débuts, a fait des progrès considérables, en particulier depuis l’acquisition de la technologie d’encapsulation cellulaire (ECT), déterminant un nouvel axe prioritaire que sont les maladies de l’¦il, où il existe clairement des besoins non satisfaits et des marchés potentiels considérables », déclare le Docteur Laurent Ganem, Directeur Associé chez Apax Partners, qui va devenir Administrateur de Neurotech. « Avec cette importante levée de fonds, nous sommes très heureux de soutenir Tom Shepherd et son équipe dans les futurs développements de la société. »

Press contact : Neurotech Dr. Tom Shepherd – +33-1 60 87 89 13- t.shepherd@neurotech.fr

Andrew Lloyd & Associates Gilles Petitot – 01 43 22 79 56 – gilles@ala.com

Visit website http://ww.neurotech.fr


Sophia-Antipolis, le 22 mai 2001 – NicOx S.A. (Nouveau Marché: NICOX, code sicovam 7413) annonce la réussite de son offre d’actions sur le Nouveau Marché d’Euronext Paris. Le produit net de l’Offre pour la Société s’élève à environ 55,4 millions d’euros. Cette offre s’est réalisée par l’émission de 870 000 actions nouvelles et la cession de 150 000 actions existantes par certains actionnaires de NicOx. Le prix de l’offre a été fixé à 68,20 euros par action.

Le chef de file de l’opération était SG Cowen; Crédit Agricole Indosuez Lazard et Cazenove intervenant en qualité de co-chefs de file.

Les responsables du placement ont la possibilité d’exercer, dans les 30 jours qui viennent, une option de sur-allocation portant sur un maximum de 153 000 actions existantes supplémentaires soit 15% de l’offre totale.

Comme annoncé, le produit net de l’Offre sera consacré à la poursuite du développement des composés NicOx y compris, pour certains candidats sélectionnés, jusqu’à l’achèvement des essais cliniques de Phase II, avant de rechercher des accords de licence. Une part significative du produit net sera consacrée d’une part, au financement des programmes de recherche et développement préclinique prometteurs dans le but d’élargir le portefeuille de développement et d’autre part, au financement des études cliniques de nouveaux candidats médicaments. Pour renforcer ses activités de recherche, NicOx ouvrira un nouveau centre de recherche à Milan. Ce centre servira à la découverte et au test de nouveaux composés, y compris des dérivés nitrés de seconde génération. L’ouverture d’un bureau à Princeton, New Jersey, à la fin du mois de mai permettra le suivi des programmes de recherche en cours et des études cliniques futures aux Etats-Unis.

” Nous sommes heureux du succès de l’Offre, en particulier du fait des conditions de marché difficiles. Il confirme la reconnaissance par la communauté financière de notre position de leader sur le marché européen des biotechs et sa confiance dans l’avenir de nos composés libérateurs d’oxyde nitrique. Les fonds levés seront utilisés pour la poursuite du développement clinique de composés de NicOx déjà identifiés. Ils seront également consacrés à la recherche et permettront ainsi de diversifier notre portefeuille et de minimiser les risques. Le produit net de l’offre assurera à NicOx une plate-forme solide et compétitive pour atteindre ses objectifs de croissance continue. “, a déclaré Michele Garufi, Président-directeur général de NicOx.

Une copie du prospectus définitif composé d’un document de référence enregistré par la Commission des Opérations de Bourse sous le numéro R. 01-164 le 2 mai 2001, d’une note d’opération préliminaire visée par la Commission des Opérations de Bourse sous le numéro 01-514 le 7 mai 2001 et d’une note d’opération définitive visée par la Commission des Opérations de Bourse sous le numéro 01-600 le 21 mai 2001 est disponible, sans frais auprès de la Société: NicOx S.A. 2455, route des Dolines- Espace Gaia II – B.P. 313- 06906 Sophia Antipolis. Tel +33 (0)4 92 38 70 20, Contact: Corinne Hoff (hoff@nicox.com)

NicOx est une société pharmaceutique émergente qui exploite les propriétés récemment découvertes de l’oxyde nitrique afin de développer des médicaments plus sûrs et plus efficaces. NicOx cible plusieurs marchés thérapeutiques majeurs tels que la douleur et l’inflammation, les maladies cardio-vasculaires, les maladies respiratoires, les entéropathies inflammatoires chroniques, l’incontinence urinaire, l’ostéoporose, certains désordres dermatologiques, certains désordres hépatiques, la maladie d’Alzheimer et certains cancers. NicOx, dont le siège social se situe à Sophia-Antipolis – France, est cotée au Nouveau Marché d’Euronext Paris.


NicOX: Corinne Hoff, Corporate Communications Manager Tel : +33 (0)4 92 38 70 20 hoff@nicox.com

Euro RSCG Omnium : Marie-Carole de Groc Tel : +33 (0)1 41 34 40 49 marie-carole.de-groc@eurorscg.fr

Visit website http://www.nicox.com


EnvoyWorldWide Inc., the leading provider of enterprise application messaging solutions, has secured eight million dollars in second round venture funding, which fully funds the company’s operations. Leading this round of financing is Longworth Venture Partners. Also contributing are previous investors Battery Ventures and Sofinnova Partners. Building on its strong momentum of the past year, EnvoyWorldWide will use the new funds to develop and expand operations, enabling them to provide services that meet the business-critical notification needs of their growing customer base. Jim Savage, partner of Longworth Venture Partners will join the company’s Board of Directors.

“Battery Ventures has built its business by partnering with leaders and our continued investment in EnvoyWorldWide signifies our recognition and support of their dominance in the enterprise application messaging space.” Todd A. Dagres, general partner at Battery Ventures. “Their services represent the next wave of significant business communications technologies, as is evidenced by the caliber of EnvoyWorldWide’s rapidly growing customer base of over 50 corporate customers, including such innovation-driven companies as OAG Worldwide [a member of the Reed Elsevier group], CCBN, FT Interactive Data, Singapore Telecom, TSI Telecommunications [a subsidiary of Verizon], and Electric Insurance Company.” Designed to solve the challenge of reaching professionals in today’s mobile business environment, EnvoyWorldWide’s communications platform provides companies with outbound, one-to-many, actionable communications that enable the worldwide delivery of business-critical messaging, instantly and simultaneously. Messages are delivered via the wired or wireless communications method each recipient prefers — phone, fax, email, pager, SMS, WAP, or other wireless device. EnvoyWorldWide’s messaging solutions are an integral part of helping companies maximize investment in enterprise applications by linking workflow with communications infrastructure.

“The commitment and confidence shown in our technology, people and opportunity by our investors differentiates EnvoyWorldWide within our market and strengthens our leadership position,” Alain Dasté, co-founder and CEO of EnvoyWorldWide. “This investment, made during this challenging funding period, will enable us to exploit a large and growing market opportunity as major corporations recognize the necessity and business value of automated outbound communications solutions.”

“Sofinnova has long recognized EnvoyWorldWide’s vision, strategy and commitment to creating innovative communications solutions serving the world’s wired and wireless professionals,” Olivier Protard, partner, Sofinnova Partners. “We look forward to integrating EnvoyWorldWide into the European business community and leveraging our contacts to help them grow even faster.”

About Battery Ventures: Battery Ventures (www.battery.com) is one of the world’s largest venture capital firms specializing in early stage technology investments. With a team of over 50 experienced professionals, Battery leverages its bandwidth, industry expertise, and capital to actively guide emerging technology companies to category dominance. Since 1983, the firm has invested worldwide in over 130 companies across the communications, software and Internet/e-Business industries. From its offices in Wellesley, MA and San Mateo, CA, the partnership manages over $1.8 billion in committed capital.

About Longworth Venture Partners: Longworth Venture Partners (www.longworth.com) is an active, early-stage technology venture firm that focuses on investments in four sectors–Internet Media, e-Commerce, Enterprise Software and IT Services. Based in the Boston area, Longworth Venture Partners is unique because of the depth of successful operating experience among its investment professionals. Longworth works closely with entrepreneurs to leverage that operating experience and to help guide and accelerate the growth of successful companies. Recent investments include Softricity, Inc., eMaven, Inc., Digital Paper Corporation, Dirig Software, Inc., Canopy International and Roving Software.

About Sofinnova Partners: Based in Paris, the Sofinnova Partners (sofinnova.social-unit.fr) team consists of 7 partners, managing close to 500 million Euros. Sofinnova Partners invests in start-up and early stage companies, both in Information Technologies and Life Sciences. In Information Technologies, Sofinnova Partners was a founding investor in companies such as BVRP, Egide, Multimania, Maximiles and Atomz. Since 1996, Sofinnova Partners has made 50 investments, including 31 as lead investor.

About EnvoyWorldWide: Headquartered in Billerica, Massachusetts, EnvoyWorldWide is the industry leader in solving the challenge of reaching professionals in today’s mobile business environment. Leading companies worldwide are using EnvoyWorldWide’s enterprise application messaging platform to distribute business-critical information to customers, employees, partners and suppliers via each recipient’s preferred method of communication. Organizations use EnvoyXpress, EnvoyWorldWide’s core service, for applications ranging from improved resource scheduling and proactive customer notification to product delivery and logistical support. EnvoyWorldWide’s services help companies slash operating costs, boost productivity, improve competitive advantage, and cultivate customer loyalty.

Visit website http://www.envoyww.com